natural pharmaceuticals derived From Cannabis and other medicinal plants

Recently Received Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR topical product

Sponsored
Tetra Bio-Pharma Inc. Profile

Tbp large new

 

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Signed a letter of intent with a major player of the healthcare specialty industry
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001. 
  • Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
  • Focused on expanding commercialization partnerships internationally for product pipeline - Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected 
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control. 
  • Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb

 

 

                   

Company Interviews

 

  

 

Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • Pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

 

12 Month Stock Chart

Last changed at 13-Oct-2017 03:58PM by AGORACOM